Keenova's Strong Fourth Quarter Performance Reflects Brand Transition Success Keenova Therapeutics showcases impressive Q4 results, driven by strong sales in Acthar Gel and XIAFLEX, as the company transitions successfully into a branded therapeutics entity.

Keenova's Strong Fourth Quarter Performance Reflects Brand Transition Success #Ireland #Dublin #XIAFLEX #Acthar_Gel #Keenova

Keenova Announces Promising New Findings on TERLIVAZ® at SHM Converge Conference Keenova Therapeutics has unveiled crucial insights into TERLIVAZ® (terlipressin) for HRS-AKI during the SHM Converge 2026, illustrating its real-world use and impact.

Keenova Announces Promising New Findings on TERLIVAZ® at SHM Converge Conference #United_States #Dublin #Terlipressin #Keenova #HRS-AKI

Keenova Presents Promising Clinical Findings on Plantar Fibromatosis Treatment at ACFAS Annual Meeting Keenova Therapeutics has unveiled clinical data on a nonsurgical treatment for plantar fibromatosis. The findings, revealed at the ACFAS meeting, show promising safety and effectiveness.

Keenova Presents Promising Clinical Findings on Plantar Fibromatosis Treatment at ACFAS Annual Meeting #Ireland #Dublin #Clinical_Data #Plantar_Fibromatosis #Keenova

Keenova Achieves 100,000 Patients in Peyronie's Disease Treatment Milestone Keenova Therapeutics marks a significant achievement, with 100,000 patients prescribed XIAFLEX for Peyronie's disease, aiming to enhance awareness and diagnosis.

Keenova Achieves 100,000 Patients in Peyronie's Disease Treatment Milestone #Ireland #Dublin #Peyronie's_Disease #XIAFLEX #Keenova

Keenova's New Presentation Enhances Understanding of Dupuytren's Contracture Keenova Therapeutics is set to present new insights on Dupuytren's contracture at the AAHS Annual Meeting, focusing on patient perceptions and treatment experiences.

Keenova's New Presentation Enhances Understanding of Dupuytren's Contracture #Ireland #Dublin #XIAFLEX #Dupuytren's_Contracture #Keenova

Mallinckrodt's New Journey: Introducing Keenova Therapeutics Post Spin-Off of Par Health Mallinckrodt completes the spin-off of Par Health and unveils Keenova Therapeutics, focusing on innovative therapies for unmet patient needs.

Mallinckrodt's New Journey: Introducing Keenova Therapeutics Post Spin-Off of Par Health #Ireland #Dublin #Mallinckrodt #Par_Health #Keenova